Table 1.
Demographic Data of Patients
| Factors | LMWH Group, n = 88 (40%) | Non-AC With VTE Group, n = 22 (10%) | Non-VTE Group, n = 110 (50%) |
|---|---|---|---|
| Mean age at presentation, years (range) | 58 (21-84) | 61 (41-85) | 59 (21-85) |
| Male gender | 51 (58%) | 12 (55%) | 57 (52%) |
| Diagnosis | |||
| Glioblastoma | 80 (91%) | 21 (95%) | 103 (94%) |
| Anaplastic glioma | 8 (9%) | 1 (5%) | 7 (6%) |
| IDH | |||
| Mutated | 3 (3%) | 0 (0%) | 6 (6%) |
| Wild type | 45 (51%) | 7 (32%) | 41 (38%) |
| Not assessed | 40 (47%) | 15 (68%) | 62 (57%) |
| Extent of resection | |||
| Biopsy | 28 (32%) | 5 (23%) | 30 (27%) |
| Subtotal resection | 42 (48%) | 14 (64%) | 60 (55%) |
| Gross total resection | 18 (20%) | 3 (14%) | 20 (18%) |
| Treatment | |||
| RT and temozolomide | 78 (89%) | 20 (91%) | 96 (87%) |
| Bevacizumab | 45 (51%) | 8 (36%) | 45 (41%) |
| Development of intracranial hemorrhage | 19 (26%) | 3 (14%) | 21 (19%) |
| Median time from HGG diagnosis to development of VTE in months | 3.3 | 5.1 | NA |
| Median time from VTE diagnosis to development of ICH in weeks | 8.8 | 3.7 | NA |
| Median survival from time of surgery in years (95% CI) | 1.5 (1.2-1.7) | 1.3 (0.8-1.8) | 1.5 (1.2-1.8) |
| Median survival from time of VTE diagnosis in years (95% CI) | 0.8 (0.5-1.0) | 0.7 (0.2-1.2) | NA |
Abbreviations: AC, anticoagulation; CI, confidence interval; ICH, intracranial hemorrhage; LMWH, low molecular weight heparin; NA, not applicable; RT, radiation therapy; VTE, venous thromboembolism.